吸入镇静与丙泊酚在ICU呼吸衰竭中的比较(INSPiRE-ICU2):多中心随机对照试验研究方案
INSPiRE-ICU2是一项3期、多中心、随机、对照、评估者盲法的非劣效性试验,计划在美国16家医院纳入235例需有创机械通气的成人ICU患者,按1.5:1随机接受经Sedaconda ACD-S吸入异氟烷或静脉丙泊酚镇静,主要终点为治疗期间无补救镇静时镇静深度维持于Richmond躁动-镇静评分-1至-4目标范围的时间百分比。
要点
- 异氟烷经Sedaconda ACD-S吸入,与静脉丙泊酚按1.5:1随机比较。
- 主要终点为无补救镇静时镇静深度处于目标范围的时间百分比。
- 次要优效性结局包括阿片类药物暴露、苏醒时间、认知恢复及自主呼吸努力保留。
核心结论
- INSPiRE-ICU2试验将帮助确定异氟烷在ICU依赖呼吸机成人患者镇静中的潜在作用。
研究设计与样本
- 3期、多中心、随机、对照、评估者盲法非劣效性试验,在美国16家医院纳入235例需有创机械通气期间持续镇静的成人ICU患者。
- 患者按1.5:1随机接受经Sedaconda ACD-S吸入异氟烷或静脉丙泊酚镇静,预计治疗至少12小时,最长48(±6)小时或直至不再需要持续镇静,以先发生者为准。
主要发现
- 主要终点为治疗期间无补救镇静时镇静深度维持于Richmond躁动-镇静评分-1至-4目标范围的时间百分比。
- 次要优效性结局包括阿片类药物暴露、苏醒时间、治疗结束后认知恢复及自主呼吸努力保留。
- 采用估计目标框架及对镇静深度、疼痛和认知恢复的盲法评估。
关键数值与推荐
- 镇静深度目标范围为Richmond躁动-镇静评分-1至-4。
- 治疗时长预计至少12小时,最长48(±6)小时。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients undergoing invasive mechanical ventilation often require pharmacologic sedation to facilitate tolerance of this life-sustaining intervention, but sedatives currently used in routine care have substantial limitations. Isoflurane is an inhaled volatile anesthetic with pharmacologic properties potentially suitable to sedation of ventilator-dependent critically ill patients, but need for specialized drug administration equipment has limited its use historically to general anesthesia in the operating theatre. This trial will evaluate isoflurane, administered using a novel drug delivery system, for sedation of ventilator-dependent adult intensive care unit (ICU) patients in the United States (US). METHODS: The Inhaled Sedation versus Propofol in Respiratory Failure in the ICU (INSPiRE-ICU2) is a phase 3, multicenter, randomized, controlled, assessor-blinded non-inferiority trial that will evaluate efficacy and safety of inhaled isoflurane delivered via the Sedaconda ACD-S, compared to intravenous propofol, for sedation of mechanically ventilated adult ICU patients. At 16 US hospitals, 235 enrolled patients requiring continuous sedation during invasive mechanical ventilation will be randomized in 1.5:1 ratio to inhaled isoflurane or intravenous propofol for sedation. Treatment duration is expected to be at least 12 h and may last up to 48 (± 6) h or until no longer needing continuous sedation, whichever occurs first. The primary endpoint is the percentage of time sedation depth is maintained within the targeted range (Richmond Agitation Sedation Scale - 1 to - 4), in the absence of rescue sedation, during the treatment period. Secondary superiority outcomes include opioid exposure, wake-up time, cognitive recovery after end-of-treatment, and preservation of spontaneous breathing effort. DISCUSSION: The INSPiRE-ICU2 trial will help determine the potential role of isoflurane for sedation of ventilator-dependent adult patients in the ICU. Key trial design features, including adoption of the estimand framework and blinded assessments of sedation depth, pain, and cognitive recovery, will ensure a rigorous evaluation of isoflurane for ICU sedation. TRIAL REGISTRATION: ClinicalTrials.gov, NCT05327296. First registered on April 5, 2022.
引用
- O'Gara B, Serra AL, Englert JA, et al. Inhaled sedation versus propofol in respiratory failure in the ICU (INSPiRE-ICU2): study protocol for a multicenter randomized controlled trial. Trials. 2025. PMID: 40165305. doi:10.1186/s13063-025-08791-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。